BCR-ABL serves as a vital biomarker for the diagnosis, classification, prognosis, and monitoring of therapeutic efficacy of tyrosine kinase inhibitors in leukemia patients.

PHLseek™ using Bio-Rad QX200™ droplet digital PCR platform, a standard PCR reaction can be distributed into a large number of tiny reactors, and through "single-molecule template PCR amplification", absolute quantification can be achieved with a sensitivity of up to 1‰.

The platform's unique droplet-based digital PCR technology represents one of the most sensitive and absolutely quantitative methods available for gene mutation detection worldwide, ensuring the reliable identification of low-level BCR-ABL.